Thermo Fisher Scientific announced that the Oncomine™ Comprehensive Assay Plus* is now available on the Ion Torrent™ Genexus™ System* helping accelerate precision oncology research. The Oncomine Comprehensive Assay Plus detects a broad range of genomic alterations in 517 genes and will now be able to deliver comprehensive genomic profiling (CGP) results as soon as the next day, enabled by Ion Torrent technology and easy, automated workflows.

CGP facilitates the simultaneous analysis of a broad range of biomarkers in one test to maximize insights on the underlying oncogenic drivers in a timely manner. Already available on the Ion GeneStudio™ S5 systems*, the Oncomine Comprehensive Assay Plus detects single-nucleotide variants, insertions and deletions, copy number variations, and fusions. Additionally, the assay detects genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB) and microsatellite instability (MSI). With the capabilities of the Genexus System, researchers can now detect a broad range of these important biomarkers, quickly and easily.

“We have been waiting for this complete and rapid CGP solution that includes all the relevant biomarkers including TMB, MSI and HRD,” said Hector M Alcaraz, MS, Founder of Imagene Health, SA de CV, an early access user of the Oncomine Comprehensive Assay Plus on the Genexus System. “This will make CGP more accessible to our local markets so that we can drive the future of precision medicine forward.”

The Genexus System is an automated and integrated NGS platform capable of delivering NGS results as soon as the next day. With end-to-end automation that requires less hands-on time, the Genexus System makes genomic profiling accessible to more researchers with varying levels of experience. Now, with the Oncomine Comprehensive Assay Plus available on the Genexus System, research teams can leverage this end-to-end solution to deliver accurate and robust CGP results as soon as the next day.

“In recent years, new genomic insights have played an essential role in advancing our understanding of human health and driving novel drug development,” said Kathy Davy, president of Clinical Next Generation Sequencing at Thermo Fisher Scientific. “The addition of the Oncomine Comprehensive Assay Plus on the Genexus System brings the benefits of rapid CGP to more labs, empowering researchers to leverage more comprehensive results at a much faster pace and accelerate what could be life-saving research.”